The Initial Public Offering subscription period commences today

Idag inleds teckningstiden i CombiGene AB (publ):s noteringsemission av högst 2 500 000 aktier samt 1 250 000 teckningsoptioner. Vid fulltecknad emission tillförs CombiGene 12 500 000 kronor och vid fullt nyttjande av vidhängande teckningsoptioner ytterligare 9 375 000 kronor före emissionskostnader. CombiGene har erhållit teckningsåtaganden avseende teckning av units för 6 525 000 kronor, vilket motsvarar 52,2 procent av emissionsbeloppet. CombiGene värderas till 44 220 000 kronor (pre-money).
Läs Pressmeddelandet >>

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

 

CombiGene AB, Agavägen 52A, SE-181 55 Lidingö

 

Linked In     Twitter      Facebook